Burrows Scott L insider trades
Burrows Scott L has filed 24 Form 4s with the SEC that we hold, for Spyre Therapeutics, Inc. (SYRE) (Chief Financial Officer) and Arcutis Biotherapeutics, Inc. (ARQT) (Chief Financial Officer). Across all of them we count 0 purchases worth $0 and 36 sales worth $10.2M reported on Form 4. In the last 12 months: 0 purchases ($0) and 26 sales ($9.1M). The largest single trade was a sale of 18,232 shares of Spyre Therapeutics, Inc. worth $1.6M, dated 2026-09-02. Of 11 sales filed since we began reading the 10b5-1 checkbox, 11 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-12-28 and the latest 2026-10-02.
Spyre Therapeutics, Inc. (SYRE)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-09-03 | S, sale reported on Form 4 | 18,531 | $522.0K | 2024-09-05 |
| 2025-09-02 | S, sale reported on Form 4 | 18,428 | $299.6K | 2025-09-03 |
| 2026-03-03 | S, sale reported on Form 4 | 200 | $8.3K | 2026-03-03 |
| 2026-03-03 | S, sale reported on Form 4 | 2,300 | $93.3K | 2026-03-03 |
| 2026-04-01 | S, sale reported on Form 4 | 6,200 | $305.1K | 2026-04-03 |
| 2026-04-01 | S, sale reported on Form 4 | 1,300 | $65.0K | 2026-04-03 |
| 2026-05-01 | S, sale reported on Form 4 | 12,500 | $892.1K | 2026-05-01 |
| 2026-06-01 | S, sale reported on Form 4 | 3,100 | $223.4K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 2,599 | $183.9K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 1,801 | $125.6K | 2026-06-03 |
| 2026-06-25 | S, sale reported on Form 4 | 5,000 | $435.6K | 2026-06-26 |
| 2026-06-25 | S, sale reported on Form 4 | 10,000 | $871.4K | 2026-06-26 |
| 2026-07-01 | S, sale reported on Form 4 | 5,775 | $505.6K | 2026-07-02 |
| 2026-07-01 | S, sale reported on Form 4 | 1,725 | $152.4K | 2026-07-02 |
| 2026-08-03 | S, sale reported on Form 4 | 5,100 | $485.6K | 2026-08-05 |
| 2026-08-03 | S, sale reported on Form 4 | 2,300 | $221.5K | 2026-08-05 |
| 2026-08-03 | S, sale reported on Form 4 | 100 | $9.7K | 2026-08-05 |
| 2026-09-01 | S, sale reported on Form 4 | 900 | $77.6K | 2026-09-03 |
| 2026-09-01 | S, sale reported on Form 4 | 4,384 | $381.9K | 2026-09-03 |
| 2026-09-01 | S, sale reported on Form 4 | 2,016 | $177.5K | 2026-09-03 |
| 2026-09-01 | S, sale reported on Form 4 | 200 | $17.8K | 2026-09-03 |
| 2026-09-02 | S, sale reported on Form 4 | 18,232 | $1.6M | 2026-09-03 |
| 2026-09-30 | S, sale reported on Form 4 | 17,500 | $1.6M | 2026-10-02 |
| 2026-10-01 | S, sale reported on Form 4 | 600 | $53.4K | 2026-10-02 |
| 2026-10-01 | S, sale reported on Form 4 | 1,500 | $135.4K | 2026-10-02 |
| 2026-10-01 | S, sale reported on Form 4 | 2,100 | $193.0K | 2026-10-02 |
| 2026-10-01 | S, sale reported on Form 4 | 3,071 | $285.4K | 2026-10-02 |
| 2026-10-01 | S, sale reported on Form 4 | 229 | $21.4K | 2026-10-02 |
Arcutis Biotherapeutics, Inc. (ARQT)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-12-27 | S, sale reported on Form 4 | 12,560 | $252.1K | 2021-12-28 |
| 2022-03-01 | S, sale reported on Form 4 | 420 | $7.5K | 2022-03-03 |
| 2022-03-04 | S, sale reported on Form 4 | 293 | $4.9K | 2022-03-07 |
| 2022-03-07 | S, sale reported on Form 4 | 10 | $164 | 2022-03-07 |
| 2023-02-28 | S, sale reported on Form 4 | 416 | $6.7K | 2023-03-02 |
| 2023-03-02 | S, sale reported on Form 4 | 1,416 | $22.4K | 2023-03-02 |
| 2023-03-02 | S, sale reported on Form 4 | 18 | $297 | 2023-03-02 |
| 2023-03-06 | S, sale reported on Form 4 | 291 | $4.4K | 2023-03-08 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1853327) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms